Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Adenocarcinoma 2Thromboembolism 1Pancreatic Ductal Adenocarcinoma 1Neoplasms 1

Interventions

Enoxaparin 3Tinzaparin 2Saline Solution 2Heparin, Low-Molecular-Weight 2Heparin 2Gemcitabine 2Fondaparinux 2Dalteparin 2130-nm albumin-bound paclitaxel 2palbociclib 1enoxaparin sodium 1edoxaban 1apixaban 1Warfarin 1Tranexamic Acid 1Sodium Chloride 1Sodium Bicarbonate 1Rivaroxaban 1Pentetic Acid 1PEGPH20 1Minocycline 1Ketoconazole 1Fluorodeoxyglucose F18 1Fluoridation 1Estramustine 1Enzyme-Linked Immunosorbent Assay 1Doxorubicin 1Docetaxel 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thromboembolism × PEGPH20 × Clear all
NCT02921022 2025-11-26

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Memorial Sloan Kettering Cancer Center

Phase NA Active not recruiting
110 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡